Furazolidone Quadruple Regimen Eradicate H. Pylori Infection
Summary
Research protocol: Experimental group: First line solution (furazolidone regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + furazolidone 100 mg, twice daily, for 14 days. Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days. Control group: First line solution (clarithromycin regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + clarithromycin 500 mg, twice a day, for 14 days. Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days. Main study endpoint: The difference in the eradication rate of H. pylori infection between the furazolidone quadruple regimen and the clarithromycin quadruple regimen. Secondary study endpoint: 1. Safety and compliance of the furazolidone quadruple regimen. 2. Comparison of high-dose dual therapy with furazolidone quadruple therapy and clarithromycin quadruple therapy on H. pylori eradication rate. 3. 1-year recurrence and recurrence rate of H. pylori infection.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Background | Amoxicillin | Other / unclassified | 1000 mg | — |
| Background | Esomeprazole | Small molecule | 20 mg | — |
| Background | colloidal bismuth pectin | Unknown | 200 mg | — |